iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
20 nov. 2024 16h30 HE
|
iRhythm
SAN FRANCISCO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and...
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
18 nov. 2024 08h15 HE
|
iRhythm
SAN FRANCISCO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the results of five new studies presented at the American Heart Association’s 2024...
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
05 nov. 2024 16h30 HE
|
iRhythm
SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
30 oct. 2024 17h15 HE
|
iRhythm
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients FDA...
iRhythm Technologies Announces Third Quarter 2024 Financial Results
30 oct. 2024 16h08 HE
|
iRhythm
SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and...
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
28 oct. 2024 08h02 HE
|
iRhythm
Hypertrophic cardiomyopathy (HCM) is a genetic heart condition affecting about 1 in 500 people and is one of the leading causes of sudden cardiac death (SCD) in people under 35, including among...
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
21 oct. 2024 16h05 HE
|
iRhythm
SAN FRANCISCO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and...
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
16 oct. 2024 16h05 HE
|
iRhythm
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
iRhythm Technologies Announces Japanese Regulatory Approval of the Zio® ECG Monitoring System, the First Product to Deliver Arrhythmia Monitoring Service Utilizing Artificial Intelligence
11 sept. 2024 08h05 HE
|
iRhythm
Zio ECG monitoring system is the only fourteen-day cardiac monitoring service in its category to receive Japanese regulatory approval as an improved device without a clinical trialZio ECG monitoring...
iRhythm Unveils Data Demonstrating Superior Real-World Performance of Next-Generation Zio® Monitor at HRX 2024 Meeting
09 sept. 2024 08h05 HE
|
iRhythm
New data shows iRhythm’s next-generation Zio monitor LTCM patch ECG device superior real-world performance compared to prior generation device.